Proven DNA results to improve your patients’ blood pressure therapy.

Geneticure optimizes prescription drug therapy by using your patients’ DNA to guide their blood pressure treatment with a new, actionable tool, supported by clinical evidence to help you provide even better care for your hypertension patients.

Developed by scientific leaders in their fields, Geneticure takes an evidence-first approach to making the promise of personalized medicine a reality.

With a simple, non-invasive cheek-swab, Geneticure uses a proprietary algorithm to analyze 17 genotypes in 11 genes and identifies unique markers in a patient’s genetic code to determine how well their body will respond to each blood pressure medication. The test assesses hypertension treatment in a comprehensive integrative nature, from drug metabolizing enzymes to receptors that are important to heart, blood vessel and kidney function, with a focus on and appreciation of the complexity of the disease.

Register as a provider and order your patients’ geneticure test kits.

Clinically proven genetic testing for your patients.

Our actionable results allow you to focus on what matters most — your patients. Introduce us to your practice and a Geneticure representative will contact you to discuss any questions you might have and help get you started sending us samples.

Reducing cost and improving care.

Geneticure helps your practice achieve cost containment and quality improvements. Based on data from a retrospective clinical trial, Geneticure has been evaluated and shown to provide estimated economic benefits in the study “Pharmacoeconomic Benefit of a Multi-Gene Hypertension Panel,” where the implementation of a multi-gene panel shows a significant and individual economic impact.1,2

Leaders in pharmacogenomics research.

We continuously invest in highlighting the clinical advantages of pharmacogenomics.

Presentations at national and international meetings

Multi-gene Pharmacogenetics and Blood Pressure Control in Patients with Hypertension. MW Johnson, R Sprissler, TP Olson, GW Beenken, and EM Snyder. Presented at the American Society for Health-System Pharmacies, 2016. The FASEB Journal, 30(1) 942.1.

Time to Blood Pressure Control According to Drug Class in Patients with Hypertension. MW Johnson, R Sprissler, TP Olson, GW Beenken, and EM Snyder. Presented at the American Society for Health-System Pharmacies, 2016. The FASEB Journal, 30(1) 942.12.

The Integrative Nature of Pharmacogenetics of Hypertension: Moving Beyond Drug Metabolizing Enzymes. EM Snyder, R Sprissler, and TP Olson. Presented at the Mayo Clinic Center for Individualized Medicine Annual Meeting, October, 2016.

Genes Predicting the Response to Beta-Blockade May Also Influence the Blood Pressure Response to Diuretic Therapy. EM Snyder, R Sprissler, and TP Olson. Presented at the Mayo Clinic Center for Individualized Medicine Annual Meeting, October, 2017.

Influence of genes important in renal sodium handling and the blood pressure response to a diuretic in hypertension. J Ross, D Walla, EM Snyder, R Sprissler, TP Olson, and P Phelps. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2017.

Influence of genes involved in the renin-angiotensin-aldosterone system and the blood pressure response to angiotensin receptor blockade in hypertension. D Walla, J Ross, EM Snyder, R Sprissler, TP Olson, and P Phelps. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2017.

Pharmacoeconomic Benefit of a Multi-Gene Panel and Blood Pressure Response to Hypertension Therapy. Monica Akre, Eli F. Kelley, Scott C. Snyder, Ryan Sprissler, Thomas P. Olson, and Eric M. Snyder. Presented at the Mayo Clinic Center for Individualized Medicine Annual Meeting. 2018.

Influence of beta-1 and beta-2 adrenergic receptor genotypes on echocardiographic response to selective and non-selective beta-blockade. Jerad J. Simmons, Eric M. Snyder, Audrie Ayres, Emma K. Bulock, Danielle M. Walla, Jennifer K. Ross, Monica Akre, Ryan Sprissler, Thomas P. Olson, Pamela K. Phelps. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2018.

Influence of genetic variation of beta-2 adrenergic receptors and blood pressure response to a diuretic. Audrie Ayres, Eric M. Snyder, Danielle M. Walla, Jennifer K. Ross, Jerad J. Simmons, Emma K. Bulock, Monica Akre, Pamela K. Phelps. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2018.

Influence of Angiotensin-Converting Enzyme (ACE) Genotypes on Blood Pressure Control and Incidence of Cough in Response to ACE Inhibition. Emma K. Bulock, Pamela K. Phelps, Eric M. Snyder, Danielle M. Walla, Jennifer K. Ross, Jerad J. Simmons, Audrie Ayres, Monica Akre, Laurie Grund, Tammy Ho, Ryan Sprissler, and Thomas P. Olson. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2018.

Relationship Between a Weighted Multi-Gene Algorithm and Blood Pressure Control in Hypertension. Pamela K. Phelps, Eric M. Snyder, Danielle M. Walla, Jennifer K. Ross, Jerad J. Simmons, Emma K. Bulock, Audrie Ayers, Monica K. Akre, Ryan Sprissler, and Thomas P. Olson. To be presented at: American Society of Pharmacology and Experimental Therapeutics Annual Meeting. 2019.

The Influence of β1-Adrenergic Receptor Genotype of Renal Sodium Handling and Blood Pressure Response to Angiotensin Receptor Blockers in Hypertension Patients. Eli F Kelley, Pamela K Phelps, Monica K Akre, Danielle M Walla, Jennifer K Ross, Jerad J Simmons, Emma K Bulock, Audrie Ayers, and Eric M Snyder. To be presented at: American Society of Pharmacology and Experimental Therapeutics Annual Meeting. 2019.

Peer-reviewed manuscripts

Association of a Multi-Gene Panel with Blood Pressure Medication Success in Patients with Hypertension. Eric M. Snyder, Ryan Sprissler, Micah Johnson, Greg D. Beenken, Timothy Curry, Nicholas Cassuto, and Thomas P. Olson. Under Review.

Pharmacoeconomic Benefit of a Multi-Gene Panel and Blood Pressure Response to Hypertension Therapy. Eli F. Kelley, Eric M. Snyder,Nimer Alkhatib, Scott C. Snyder, Ryan Sprissler, Thomas P. Olson, Monica Akre, and Ivo Abraham. Journal of Medical Economics.2018. Oct 22:1-8.

The Effect of Genetically Guided Mathematical Prediction and the Blood Pressure Response to Pharmacotherapy in Hypertension Patients. Eli F. Kelley, Thomas P. Olson, Timothy Curry, Ryan Sprissler, and Eric M. Snyder. Under Review.

Relationship Between a Weighted Multi-Gene Algorithm and Blood Pressure Control in Hypertension. Pamela K. Phelps, Eric M. Snyder, Danielle M. Walla, Jennifer K. Ross, Jerad J. Simmons, Emma K. Bulock, Audrie Ayers, MonicaK. Akre, Ryan Sprissler, and Thomas P. Olson. Under Review.

completed and ongoing trials

Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension. Clinicaltrials.gov identifier: NCT02524873. Completed.

Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension. Clinicaltrials.gov identifier: NCT02988245. Ongoing.

Association Between a Genetic Algorithm to Predict Hypertension Therapy and Response to Treatment. Clinicaltrials.gov identifier: NCT03292900. Completed.

Peace of mind for your patients.

Geneticure delivers the detailed information you need to help put your patients on the path towards controlling their blood pressure fast and effectively.

Your questions answered.

Please visit our Frequently Asked Questions for more information about Geneticure.

  1. Akre, M. (2018, September). Pharmaco-economic Benefit of a Multi-Gene Hypertension Panel. Center for Individual Medicine, Rochester, MN.
  2. EF Kelley, EM Synder, N Alkhatib, et al. Pharmacoeconomic Benefit of a Multi-Gene Panel and Blood Pressure Response to Hypertension Therapy. J of Medical Economics. 2018, Oct 22:1-8.
  3. https://clinicaltrials.gov/ct2/show/NCT03292900
  4. MW Johnson, R Sprissler, TP Olson, et al. Time to Blood Pressure Control According to Drug Class in Patients with Hypertension. Presented at the American Society for Health-System Pharmacies, 2016. FASEB Journal. 30(1) 942.12.